Table 3.
Fitting parameters of concentration–response relationships of the sulfonylureas and glinides concentrations versus the percent changes of the KATP channel current in different muscle phenotypes
| Treatment | Emax (%) | Emin (%) | EC50 (10−6 mol/L) | Slope factor n |
|---|---|---|---|---|
| Glibenclamide | ||||
| FDB | −98.9 ± 91 | −2.4 ± 1 | 1.08 ± 0.21 | 0.91 ± 0.01 |
| EDL | −78.1 ± 61 | −2.9 ± 1 | 30.7 ± 71 | 0.82 ± 0.02 |
| SOL | −70.5 ± 41 | −3.2 ± 0.7 | 35.1 ± 21 | 0.75 ± 0.03 |
| Tolbutamide | ||||
| FDB | −40.6 ± 8 | −1.59 ± 0.2 | 170.1 ± 11 | 0.61 ± 0.04 |
| EDL | −26.3 ± 5 | – | – | – |
| SOL | −19.1 ± 3 | – | – | – |
| Glimepiride | ||||
| FDB | −45.4 ± 9 | −2.3 ± 0.1 | 36.7 ± 10 | 0.93 ± 0.03 |
| EDL | −80.4 ± 71 | −1.9 ± 0.2 | 48.8 ± 81 | 0.91 ± 0.02 |
| SOL | −75.3 ± 61 | −2.1 ± 0.3 | 55.1 ± 111 | 0.90 ± 0.05 |
| Repaglinide | ||||
| FDB | −75.4 ± 9 | −1.3 ± 0.2 | 1.67 ± 0.91 | 0.93 ± 0.04 |
| EDL | −70.4 ± 10 | −4.9 ± 0.5 | 55.6 ± 111 | 0.82 ± 0.07 |
| SOL | −78.3 ± 8 | −3.1 ± 0.5 | 17.11 ± 41 | 0.90 ± 0.08 |
| Nateglinide | ||||
| FDB | −48.7 ± 7 | −1.3 ± 0.4 | 132.1 ± 18 | 0.78 ± 0.07 |
| EDL | −50.3 ± 6 | −4.9 ± 0.5 | 120.1 ± 11 | 0.67 ± 0.09 |
| SOL | −55.2 ± 9 | −3.1 ± 1 | 110.1 ± 21 | 0.71 ± 0.08 |
The data are the mean ± SE of the maximal drug effect, Emax; the minimal drug effect, Emin; the concentration needed to cause the 50% change in the drug effect, EC50; the hill slope of the curve, n. Treatment indicates the drug treatments in different muscles. FDB, flexor digitorum brevis; SOL, soleus; EDL, extensor digitorum longus.
1
Data significantly different evaluated by the one-way analysis of variance in different muscles (P < 0.05).